araag2/HINT huggingface dataset:
Clinical trial NCT01186419 (phase 2, status: completed)
Conditions: transfusional iron overload, beta-thalassemia
ICD codes: E87.70, E87.79, E87.71, D56.1, D56.2, D56.5, D57.42, D57.44, D57.432, D57.439
Drugs: spd602 (fbs0701, ssp-004184)
SMILES: COCCOCCOCCOC1=C(O)C(=CC=C1)C1=N[C@](C)(CS1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Transfusional iron overload due to: hereditary anemias such as sickle cell disease,
             β-thalassemia and Diamond-Blackfan anemia; acquired anemias such as Myelodysplastic
             Syndrome and other forms of bone marrow failure. Patients must also be
             transfusion-dependent and require chronic treatment with deferoxamine, deferasirox,
             and/or deferiprone.

          -  Willing to discontinue all existing iron chelation therapies throughout study period.

          -  Serum ferritin greater than 500 ng/mL at Screening.

          -  Baseline liver iron concentration and cardiac MRI T2* per protocol requirements.

          -  Mean of the previous three pre-transfusion hemoglobin concentrations greater than or
             equal to 7.5 g/dL.

          -  Agrees to use an approved method of contraception throughout study period.

        Exclusion Criteria:

          -  As a result of medical review, physical examination or Screening investigations, the
             Principal Investigator considers the patient unfit for the study.

          -  Non-elective hospitalization within the 30 days prior to Baseline testing. (Patients
             with sickle cell anemia who are admitted to the hospital for management of sickle
             crisis pain whose uncomplicated hospital course was four days or less and who, 14 days
             prior to Baseline testing, have returned to their previous health status are
             acceptable.)

          -  Evidence of clinically relevant oral, cardiovascular, gastrointestinal, hepatic,
             renal, endocrine, pulmonary, neurologic, psychiatric, immunologic, bone marrow or skin
             disorder as determined by the Investigator.

          -  Evidence of significant renal insufficiency; possible examples include: serum
             creatinine above the upper limit of normal, proteinuria greater than 2 gm per day or
             calculated creatinine clearance of less than 60 mL/minute.

          -  Cardiac left ventricular ejection fraction outside of protocol requirements.

          -  Known sensitivity to magnesium stearate, croscarmellose sodium or FBS0701.

          -  Platelet count below 100,000/µL and/or absolute neutrophil count less than 1500/mm3 at
             Screening and <50% at Baseline testing by MRI

          -  Alkaline phosphatase, AST or ALT outside of protocol requirements.

          -  Liver Function Tests: ALT >5 times the local upper limit of normal on two occasions in
             the previous 12 months or ALT at Screening >200 IU/L

          -  Use of any investigational agent within the 30 days prior to the Baseline testing.
Clinical trial NCT00553943 (phase 2, status: completed)
Conditions: lymphoma, non-hodgkin, diffuse large b-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, cytarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Primary cerebral or oculocerebral NHL not previously treated with chemotherapy or
             radiotherapy and diffuse large B-cell lymphomas, with cerebral and / or neuromeningeal
             involvement at diagnosis.

          -  Diagnosis proved by histological or cytological examination of cerebral specimens, CSF
             or vitreous humour.

          -  Diffuse large cell CD20+ lymphoma.

          -  Men or women between the ages of 18 and 60 years.

          -  Presence of a measurable target to evaluate response.

          -  Negative serological tests for HIV, hepatitis B (except in cases of vaccination),
             hepatitis C.

          -  Life-expectancy ≥ 3 months

          -  Patient having given written consent to participate in this study.

        Exclusion Criteria:

          -  CD20- lymphoma.

          -  History of indolent lymphoma, treated or untreated.

          -  Contraindication for one of the products used in polychemotherapy.

          -  Known hypersensitivity to mouse antibodies.

          -  Absence of measurable target to evaluate response.

          -  History of cancer in the 5 years prior to inclusion except for cutaneous basocellular
             carcinomas and non-invasive carcinomas of the neck of the uterus.

          -  Cardiac contraindication to treatment with anthracyclines or to hyperhydration:

        SEVERE DISTURBANCE OF HEART RHYTHM VENTRICULAR EJECTION FRACTION BELOW 50% HISTORY OF
        RECENT MYOCARDIAL INFARCTION

          -  Previously known severe renal insufficiency and/or creatinaemia >150 µM/L (apart from
             invasion of the kidneys by the lymphoma).

          -  Total bilirubin >30 µmol/L, ASAT, ALAT >2.5 times the upper normal value (apart from
             invasion of the liver by the lymphoma).

          -  Insufficient medullary reserve: PNL < 1 G/L and platelets <100 G/L (apart from
             invasion of the medulla by the lymphoma).

          -  History of organ transplantation or other causes of severe immunosuppression.

          -  Pregnant woman.

          -  Patient incapable of keeping to regular monitoring.
Clinical trial NCT01911845 (phase 2, status: completed)
Conditions: chronic hepatitis c infection, chronic hepatitis c
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2, B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: abt-450/r/abt-267, abt-333, ribavirin (rbv)
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Females must be practicing specific forms of birth control on study treatment, or be
             postmenopausal for more than 2 years or surgically sterile.

          -  Chronic HCV infection prior to study enrollment.

          -  Screening laboratory result indicating HCV genotype 1-infection.

          -  Subject must be treatment naive or previous pegylated interferon/ribavirin treatment
             experienced.

          -  Subjects must be on a stable opioid replacement therapy of methadone or buprenorphine
             ± naloxone for at least 6 months prior to screening.

        Exclusion Criteria:

          -  Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human
             Immunodeficiency virus antibody (HIV Ab) at screening.

          -  Prior therapy with direct acting antiviral agents for the treatment of HCV, including
             telaprevir and boceprevir.

          -  Females who are pregnant or plan to become pregnant, or breastfeeding, or males whose
             partners are pregnant or planning to become pregnant within 7 months (or per local RBV
             label) after their last dose of study drug.

          -  Any current or past clinical evidence of cirrhosis such as ascites or esophageal
             varices, or prior biopsy showing cirrhosis, e.g., a Metavir Score of >3 or Ishak score
             of > 4.
Clinical trial NCT00095576 (phase 2, status: terminated)
Conditions: aids, hiv infections
ICD codes: Z21
Drugs: comparator: placebo
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy, HIV seronegative adults at high risk of acquiring HIV infection

          -  Cannot have previously received an investigational vaccine

        Exclusion Criteria:

          -  In a monogamous relationship with an HIV-1 seronegative partner for > 1 year

          -  History of anaphylaxis and/or allergy to vaccine components, including Tris buffer,
             MgCl2, and polysorbate 80 (TWEEN)

          -  Received an immune globulin or blood derived products 3 months before injection with
             the first dose of vaccine/placebo or scheduled within 14 days after injection

          -  Previously vaccinated with a live virus vaccine within 30 days before injection with
             the first dose of vaccine or scheduled within 14 days after injection

          -  Previously vaccinated with an inactivated vaccine within 5 days before injection with
             the first dose of vaccine or scheduled within 14 days after injection

          -  Known history of immunodeficiency

          -  History of malignancy (with some exceptions)

          -  Contraindication to intramuscular (IM) injection such as anticoagulant therapy or
             thrombocytopenia

          -  Female subject who is pregnant or breast feeding, or expecting to conceive or donate
             eggs through Week 30 of the study

          -  Male subject who is planning to impregnate or provide sperm donation through Week 30
             of the study

          -  Previously received an investigational HIV vaccine

          -  Has active drug or alcohol abuse or dependence that would interfere with adherence to
             study requirements, or endanger the subject's health while on the study

          -  Has a condition that might endanger the subject's health or interfere with the
             evaluation of the study objectives
Clinical trial NCT00246298 (phase 2, status: terminated)
Conditions: anemia, hiv
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    obi business decision not to complete any additional research in hiv.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must be documented HIV positive and on a stable antiretroviral regimen for at
             least four weeks prior to enrollment

          -  have a hemoglobin level <12.0 g/dL

          -  have not undergone cancer therapy (chemotherapy and/or radiation therapy) within 12
             months prior to enrollment

        Exclusion Criteria:

          -  History of acute, symptomatic opportunistic infection or other acute AIDS defining
             illness within six months of enrollment

          -  History of any primary hematologic disease

          -  Have anemia attributable to factors other than HIV infection (i.e. iron, or vitamin
             B12 deficiency, hemolysis, or gastrointestinal bleeding)

          -  Have Hepatitis C virus (HCV) co-infection

          -  Have uncontrolled or severe cardiovascular disease including recent myocardial
             infarction, hypertension, or congestive heart failure
Clinical trial NCT00537017 (phase 2, status: completed)
Conditions: parkinson disease, neurodegenerative diseases, central nervous system diseases, movement disorders, brain diseases
ICD codes: G20, G37.9, G37.3, G13.1, G09, G13.8, G37.8, G47.61, G25.70, G25.9, H51.9, F98.4, G25.79, G25.89, G46.8, G94
Drugs: preladenant, l-dopa, other parkinson's disease treatments
SMILES: COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must have participated in P04501.

          -  Participants must be >=30 years of age, with a diagnosis of moderate to severe
             idiopathic Parkinson's disease.

          -  Participants must have been on a regimen of L-Dopa and/or a dopamine agonist.

        Exclusion Criteria:

          -  Participants who discontinued from Study P04501 because they experienced a serious
             adverse event (SAE)

          -  Participants with any form of drug-induced or atypical parkinsonism, cognitive
             impairment, or psychosis

          -  Participants taking tolcapone

          -  Participants who are participating in any other clinical study
Clinical trial NCT00100828 (phase 2, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: irinotecan hydrochloride
SMILES: CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
Reason stopped: 
    closed due to early stopping rule
  
Eligibility criteria:

        Inclusion

          -  Histologically confirmed medullary thyroid cancer

          -  Metastatic or inoperable locoregional disease

          -  Measurable disease by CT scan

          -  18 years and over

          -  ECOG PS 0-1

        Adequate lab functions including:

          -  Granulocyte count > 1,000/mm^3

          -  Platelet count > 100,000/mm^3

          -  Bilirubin < 1.5 mg/dL

          -  ALT and AST < 2.5 times upper limit of normal

          -  No unstable or uncompensated hepatic disease

          -  Creatinine clearance > 60 mL/min

          -  No unstable or uncompensated renal disease

          -  Negative pregnancy test

          -  More than 3 months since prior biologic therapy

          -  More than 3 months since prior chemotherapy

          -  No prior radiotherapy to > 25% of bone marrow

          -  More than 3 months since prior radiotherapy

          -  Recovered from prior oncologic or other major surgery

          -  More than 30 days since prior non-approved or investigational drugs

        Exclusion:

          -  Patients with elevated calcitonin levels as the only measurement of disease are not
             eligible

          -  Unstable or uncompensated cardiovascular disease

          -  Unstable or uncompensated respiratory disease

          -  Pregnant or nursing

          -  Diarrhea ≥ grade 2 (antidiarrheals allowed)

          -  Other severe or uncontrolled systemic disease

          -  Other malignancy within the past 5 years except squamous cell or basal cell skin
             cancer or cervical cancer

          -  Illness that would preclude study participation

          -  Significant clinical disorder or laboratory finding that would preclude study
             participation
Clinical trial NCT00162279 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Eligibility criteria:

        Inclusion Criteria:

          -  All subjects who had completed the short term portion of IM101-101.
Clinical trial NCT00504543 (phase 2, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: aeb071, certican, neoral
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Eligibility criteria:

        Inclusion criteria

          -  Male and female patients 18 years or older

          -  Recipients of first kidney transplant from a deceased or living not related donor

        Exclusion criteria

          -  Need for medication prohibited in the study

          -  Patients with heart disease (own or family history)

          -  Patients or donor HIV, Hepatitis B (HBsAg) or Hepatitis C (HCV) positive

          -  Patients with high immunological risks

          -  Patients with a history of cancer

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00086775 (phase 2, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: fludarabine phosphate
SMILES: NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of B-cell chronic lymphocytic leukemia (CLL), defined as:

               -  Peripheral lymphocyte count > 5,000/mm^3

               -  Clonal CD5-, CD19-, and CD23-positive lymphocytes

          -  Refractory to OR relapsed after prior first-line therapy

          -  No CNS involvement with CLL

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Hepatitis B surface antigen negative

          -  Hepatitis C antibody negative

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Immunologic

          -  No active cytomegalovirus

          -  No prior fludarabine-associated autoimmune hemolytic anemia or immune thrombocytopenic
             purpura

          -  No active infection requiring treatment with antibiotic, antiviral, or antifungal
             agents

          -  No prior significant allergic reaction to antibody therapies that required therapy to
             be discontinued

          -  HIV negative

        Other

          -  No active secondary malignancy

          -  No other concurrent severe diseases or mental disorders

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 4 weeks since prior alemtuzumab and/or rituximab

          -  No prior bone marrow transplantation

          -  No concurrent thrombopoietin or pegfilgrastim

        Chemotherapy

          -  More than 3 weeks since prior fludarabine

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  More than 3 months since prior investigational drugs

          -  No other concurrent cytotoxic therapy
Clinical trial NCT00431613 (phase 2, status: terminated)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel, gemcitabine, carboplatin, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  histologically or cytologically confirmed, unresectable locally advanced (stage
             IIIA/IIIB) NSCLC

          -  no previous therapy for NSCLC is allowed

          -  age >18 years

          -  bidimensionally measurable disease

          -  performance status (WHO) 0-2

          -  absence of pleural effusion

          -  adequate liver (serum bilirubin < 1.5 times the upper normal limit (UNL); AST and ALT
             < 2.5 times the UNL in the absence of demonstrable liver metastases, or < 5 times the
             UNL in the presence of liver metastases); adequate renal function (serum creatinine <
             1.5 times the UNL); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x
             109 /L) function

          -  life expectancy of more than 3 months

          -  written informed consent

        Exclusion Criteria:

          -  active infection

          -  history of significant cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias)

          -  malnutrition (loss of ≥ 20% of the original body weight)

          -  performance status: 3-4

          -  sensor or motor neuropathy > grade I

          -  second primary malignancy, except for non-melanoma skin cancer

          -  psychiatric illness or social situation that would preclude study compliance

          -  pregnant or lactating women
Clinical trial NCT00278824 (phase 2, status: terminated)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: matrix transdermal fentanyl/chadd drug delivery system, placebo patch
SMILES: CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
Reason stopped: 
    difficulty identifying and enrolling eligible patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is 18 through 70 years of age.

          -  Patient has moderate to severe non-malignant chronic pain.

          -  Patient is opioid-tolerant, requires treatment with chronic opioids and is currently
             taking a dose of 50 mcg/hr transdermal fentanyl for the treatment of chronic pain.
             Patient must have been taking this dose for at least 2 weeks.

          -  Patient must be experiencing 1 to 4 episodes of target breakthrough pain (breakthrough
             pain that is related to the patient's chronic pain condition) a day while taking a
             dose of 50 mcg/hr transdermal fentanyl.

        Exclusion Criteria:

          -  Patient has active cancer.

          -  Patient has a history of substance abuse or has a substance abuse disorder.

          -  Patient is pregnant or breastfeeding.
Clinical trial NCT00444639 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: triptorelin (decapeptyl®)
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Reason stopped: 
    low recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological proven prostate cancer, locally advanced or metastatic and scheduled to
             receive hormonal deprivation therapy

          -  Life expectancy of more than 9 months

          -  Documented testosterone levels of ≥ 125 ng/dl measured by any laboratory or on site
             within the previous 6 months

        Exclusion Criteria:

          -  Has a history of hypersensitivity to the Investigational Medicinal Product or drugs
             with a similar chemical structure

          -  Has previously received a GnRH analogue, estrogens or a steroidal anti -androgen
             within the last year preceding the study

          -  Concomitant anti-coagulation treatment

          -  Patient who underwent an orchidectomy or who is scheduled to receive an orchidectomy
             during the course of this study

          -  Patient with known spinal medullar compression